A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus-Reference-Cited by-同舟云学术

A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus

Published:2020-05 Issue:5 Volume:34 Page:107555
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Lee Moon-Kyu,Kim Sin Gon,Watkins Elaine,Moon Min Kyong,Rhee Sang Youl,Frias Juan P.,Chung Choon Hee,Lee Seung-Hwan,Block Bradley,Cha Bong Soo,Park Hyeong Kyu,Kim Byung Joon,Greenway Frank

Funder

Melior Pharmaceuticals

Bukwang Pharmaceutical Co. Ltd.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. WHO global report on diabetes: a summary;Roglic;International Journal of Noncommunicable Diseases,2016

2. Pharmacologic therapy for type 2 diabetes mellitus;DeFronzo;Ann Intern Med,1999

3. Biochemistry and molecular cell biology of diabetic complications;Brownlee;Nature.,2001

4. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes;Ochman;J Pharmacol Exp Ther,2012

5. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo;Saporito;J Pharmacol Exp Ther,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-10

2. Diabetes: a review of its pathophysiology, and advanced methods of mitigation;Current Medical Research and Opinion;2024-04-04

3. Signaling pathways and intervention for therapy of type 2 diabetes mellitus;MedComm;2023-06

4. Pharmacotherapy of type 2 diabetes: An update and future directions;Metabolism;2022-12

5. New Horizons: Emerging Antidiabetic Medications;The Journal of Clinical Endocrinology & Metabolism;2022-09-15